

Remarks

I. The Amendments

The specification of the application was amended by deleting the sequence listing originally filed and entering a substitute sequence listing.

In addition, pages 6, 23, 24 and 25 of the application, were amended to include sequence identification numbers for DNA sequences.

II. Submission of Computer Readable Copy of Sequence Listing

Applicants are including herewith a 3.5 inch computer readable diskette which contains a copy of the newly submitted Sequence Listing in ASCII text.

Statements to Comply With 37 C.F.R. § 1.821 and 1.825

In compliance with 37 C.F.R. § 1.821(f) and (g), a separate Statement to support filing and submission in accordance with 37 C.F.R. §§ 1.821-1.825 is also submitted herewith.

Conclusion

In light of the present amendments and enclosures, Applicants respectfully submit that all Sequence Listing requirements have now been complied with. It is therefore respectfully submitted that this application is now in condition for substantive review.

If, in the opinion of the Examiner, a phone call may help to expedite the prosecution of this application, the Examiner is invited to call Applicants' undersigned attorney at (703) 905-2018.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Donald G. Bird

Reg. No. 25323

Tel.: (703) 905-2018

Fax: (703) 905-2500

PILLSBURY WINTHROP LLP
1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2173

DJB/amx

09733956-060101
FOI 090 " 95666260

Appendix

Version with Markings to Show Changes Made

The specification of the application was amended to enter sequence identification numbers. The changes that were made are shown below with the underlined words indicating text that was added.

On page 6 of the specification, lines 3-17 were amended as follows:

The present invention also provides purified nucleic acid sequences encoding DETH, variant thereof or fragment thereof. A preferred sequence encoding DETH is shown in SEQ ID NO:1. Nucleic acid sequence as used herein refers to an oligonucleotide, nucleotide or polynucleotide and fragments or portions thereof and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. A nucleic acid sequence encoding DETH can be obtained from mammalian cells, preferably human cells using polymerase chain reaction techniques (PCR) and appropriate primers encompassing the 3' and 5' ends of the sequence encoding DETH shown in SEQ ID NO:1 with the nucleic acid in the cells serving as a template. A nucleic acid sequence encoding DETH was obtained from clone g1727750 obtained from the Merck/Washington University EST Project, St. Louis, Missouri, USA. Clone g1727750 was made from mRNA of a human colon epithelial cell line. Suitable primers for PCR include 5' primer - ttt aga tct atg aac tca aca gaa tcc aac tct tct gcc (SEQ ID No:3) and (SEQ ID No:4) 3' primer - gtc gac cta cag cag gtc agg aag atg gct ata aac ag . Suitable polymerase reaction conditions are those generally found in the art and exemplified herein in the examples.

On page 23 of the application, lines 23-28 were amended as follows:

The novel protein DETH was identified after the assembly of expressed sequence tags (EST) sequences from a proprietary database base (Lifeseq data base, Incyte, Palo Alto, California) and the public Merck /Washington University EST sequence database. The initial identification

of these ESTs was performed by basic local alignment search tool (BLAST) analysis of the databases using the death domain sequence of RIP (SEQ ID No:5)(TNF receptor interacting protein) :

On page 24 of the application, lines 17-18 were amended as follows:

(SEQ ID NO: 3) Primer 1 - ttt aga tct atg aac tca aca gaa tcc aac tct tct gcc

(SEQ ID NO:4) Primer 2 - gtc gac cta cag cag gtc agg aag atg gct ata aac ag

On page 25 of the application, lines 8-14 were amended as follows:

For the extracellular region the following primers containing the restriction sites Bgl II/Sal I were used:

5' Bgl II for (SEQ ID NO:3) Primer 1 - ttt aga tct atg aac tca aca gaa tcc
aac tct tct gcc

3' EcoR I for (SEQ ID NO:6) Primer 3 - ttt gaa ttc caa atg ctc att gat gtc aa
atg c

For the intracellular region the following primers containing Bgl II/ Eco RI restriction sites were used:

5' Bgl II for (SEQ ID NO:7) Primer 4 - ttt aga tct cgg aaa agc tcg agg act
ctg aaa aag ggg

3' Sal I for (SEQ ID NO:4) Primer 2 - gtc gac cta cag cag gtc agg aag atg
gct ata aac ag